Vertex Pharmaceuticals, Inc. (VRTX) Blows Up Q3 Estimates
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $466.79 +3.36%
EPS Growth %: +4.4%
Financial Fact:
Product revenues, net: 409.69M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +4.4%
Financial Fact:
Product revenues, net: 409.69M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q3 EPS of $0.70, $0.53 better than the analyst estimate of $0.17. Revenue for the quarter came in at $659.2 million versus the consensus estimate of $343.42 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
